Analytical Data
-
Gene name
CD79B
-
简介
CD79B protein binds to CD79A and initiates the B cell antigen receptor complex (BCR) signaling cascade. This results in complex internalization, transport to late endosomes and antigen presentation. CD79B Protein, Cynomolgus (Biotinylated, HEK293, His-Avi) is the recombinant cynomolgus-derived CD79B protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of CD79B Protein, Cynomolgus (Biotinylated, HEK293, His-Avi) is 132 a.a., with molecular weight of 30-35 kDa.
- Application
-
Alternative Names
CD79b; B29; IGB; Ig-beta
-
Species
Cynomolgus
-
Source
HEK293
-
Tag
C-Avi;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
A0A2K5WTH8
-
Expression Region
A30-D161
-
Molecular Weight
30-35 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD79B is a crucial component of the B cell receptor (BCR) complex, playing a significant role in B cell development and immune response. It forms a heterodimer with CD79A, facilitating the transmission of signals upon antigen binding, which is essential for B cell activation, proliferation, and differentiation. Mutations or dysfunctions in CD79B are associated with various B cell malignancies, including diffuse large B cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL). As a result, CD79B has emerged as a potential therapeutic target and biomarker in these diseases. Research on recombinant CD79B proteins is vital for understanding its structural and functional properties, enabling the development of targeted therapies. These therapeutics can include monoclonal antibodies or small molecules that specifically inhibit the aberrant signaling pathways mediated by mutated CD79B. Moreover, recombinant CD79B proteins can serve as research tools to study B cell biology and the underlying mechanisms of B cell-related disorders. Understanding the role of CD79B in B cell signaling may lead to innovative strategies for treating B cell malignancies and improving patient outcomes. This research represents a promising avenue in immunology and oncology, emphasizing the importance of CD79B as both a biomarker and therapeutic target in the field of cancer research.
